Last reviewed · How we verify
Triptorelin Embonate
Triptorelin Embonate is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) that acts as a potent agonist.
Triptorelin Embonate is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) that acts as a potent agonist. Used for Prostate cancer, Breast cancer.
At a glance
| Generic name | Triptorelin Embonate |
|---|---|
| Also known as | Pamorelin |
| Sponsor | Marco Lorenzo Bonu |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to GnRH receptors in the pituitary gland, triptorelin embonate triggers a cascade of downstream effects that ultimately lead to the suppression of gonadotropin secretion, resulting in decreased levels of sex hormones such as testosterone and estrogen. This mechanism is exploited to treat hormone-sensitive cancers and other conditions.
Approved indications
- Prostate cancer
- Breast cancer
Common side effects
- Hot flashes
- Nausea
- Diarrhea
- Fatigue
- Headache
- Injection site reaction
Key clinical trials
- Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (PHASE2)
- Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (PHASE3)
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (PHASE2, PHASE3)
- Radiotherapy After Prostatectomy for Node Positive Prostate Cancer (PHASE3)
- Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (PHASE2, PHASE3)
- A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PHASE3)
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triptorelin Embonate CI brief — competitive landscape report
- Triptorelin Embonate updates RSS · CI watch RSS
- Marco Lorenzo Bonu portfolio CI